Terapia dell'iperparatiroidismo secondario nei pazienti emodializzati

Secondary hyperparathyroidism (SHPT) characterizes, by the first phases, the course of the chronic kidney disease and it has an important role in the phathogenesis of the osteitis fibrosa and the cardiovascular disease (that is responsible for the significant mortality in the uremic patients). The traditional medical therapy of the secondary hyperparathyroidism (dietetics restriction of phosphorus, phosphate bindings, calcium supplements and active metabolite of Vitamin D) results in fact inadequate for over 50% of the hemodialysis patients.